Trials / Completed

CompletedNCT00219076

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients

A Six-week, Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren 150 mg and Amlodipine 5 mg Compared to Amlodipine 5 mg and 10 mg in Hypertensive Patients Not Adequately Responsive to Amlodipine 5 mg

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 504 (planned)

Sponsor: Novartis · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

To evaluate the blood pressure lowering effect and safety of aliskiren 150 mg used in combination with amlodipine 5 mg in patients with essential hypertension not adequately responsive to amlodipine 5 mg.

Conditions

Hypertension

Interventions

Type	Name	Description
DRUG	aliskiren

Timeline

Start date: 2005-02-01
Primary completion: 2005-10-01
First posted: 2005-09-22
Last updated: 2017-05-18

Locations

2 sites across 2 countries: United States, Germany

Source: ClinicalTrials.gov record NCT00219076. Inclusion in this directory is not an endorsement.